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Abstract
Background: The bromodomain containing 1 (BRD1) gene has been implicated with transcriptional regulation,
brain development, and susceptibility to schizophrenia and bipolar disorder. To advance the understanding of BRD1
and its role in mental disorders, we characterized the protein and chromatin interactions of the BRD1 isoforms,
BRD1-S and BRD1-L.
Methods: Stable human cell lines expressing epitope tagged BRD1-S and BRD1-L were generated and used as
discovery systems for identifying protein and chromatin interactions. Protein-protein interactions were identified
using co-immunoprecipitation followed by mass spectrometry and chromatin interactions were identified using
chromatin immunoprecipitation followed by next generation sequencing. Gene expression profiles and differentially
expressed genes were identified after upregulating and downregulating BRD1 expression using microarrays. The
presented functional molecular data were integrated with human genomic and transcriptomic data using available
GWAS, exome-sequencing datasets as well as spatiotemporal transcriptomic datasets from the human brain.
Results: We present several novel protein interactions of BRD1, including isoform-specific interactions as well as
proteins previously implicated with mental disorders. By BRD1-S and BRD1-L chromatin immunoprecipitation
followed by next generation sequencing we identified binding to promoter regions of 1540 and 823 genes,
respectively, and showed correlation between BRD1-S and BRD1-L binding and regulation of gene expression. The
identified BRD1 interaction network was found to be predominantly co-expressed with BRD1 mRNA in the human
brain and enriched for pathways involved in gene expression and brain function. By interrogation of large datasets
from genome-wide association studies, we further demonstrate that the BRD1 interaction network is enriched for
schizophrenia risk.
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Conclusion: Our results show that BRD1 interacts with chromatin remodeling proteins, e.g. PBRM1, as well as
histone modifiers, e.g. MYST2 and SUV420H1. We find that BRD1 primarily binds in close proximity to transcription
start sites and regulates expression of numerous genes, many of which are involved with brain development and
susceptibility to mental disorders. Our findings indicate that BRD1 acts as a regulatory hub in a comprehensive
schizophrenia risk network which plays a role in many brain regions throughout life, implicating e.g. striatum,
hippocampus, and amygdala at mid-fetal stages.
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Background
Genetic variations in the bromodomain containing 1
(BRD1) gene located on 22q13.33 have repeatedly been
associated with both schizophrenia and bipolar disorder
[1–3]. The BRD1 locus approached genome-wide signifi-
cance (P = 3.31 × 10–7) in the most recent schizophrenia
genome-wide association study (GWAS) by the Psychiatric
Genomics Consortium using conventional statistical
methods [4]. Moreover, the locus was found genome-wide
significant using an Empirical Bayes statistical approach
and predicted to be highly replicable [5]. Furthermore, in a
schizophrenia GWAS meta-analysis (11,185 cases/10,768
controls) and a family-based replication study (3286 cases
from 1811 families) the SNP rs138880 in the promoter re-
gion of BRD1 showed the overall most significant associ-
ation [6].
BRD1 is essential for normal brain development and in-
activation of both alleles of Brd1 in mice leads to impaired
neural tube closure [7]. Co-immunoprecipitation (co-IP) of
epitope tagged and endogenous BRD1 and MYST2 from
human K562 and HEK293 cells suggest that ING4,
MEAF6, and MYST2 constitute the primary histone acetyl-
transferase complex of BRD1 [7]. Additionally, a focused
promoter ChIP-on-chip (chromatin immunoprecipitation
combined with microarray analysis) of co-expressed epi-
tope tagged BRD1 and MYST2 in human K562 cells identi-
fied a large overlap in target genes between the two
proteins suggesting a pivotal role of the BRD1/MYST2
complex in transcriptional regulation [7]. Equally, Brd1–/–
and Myst2–/– knockout mouse embryos show severely de-
creased levels of the overall histone H3K14 acetylation,
suggesting that the Brd1/Myst2 complex is responsible for
the majority of histone H3K14 acetylation during em-
bryonic development in mice [7, 8]. We have previously
reported a divergence in immunohistochemical staining
between the BRD1-S and BRD1-L isoforms in the brain [9]
as well as differential transcriptional regulation of the
Brd1-S and Brd1-L splice variants in prefrontal cortex and
hippocampus following chronic restrained stress [10] and
electroconvulsive seizures [11] in adult rats, indicating that
BRD1 isoforms can perform separate functions dependent
on the specific cell type and tissue. To gain more know-
ledge about the biological functions of BRD1 and how
these might be involved in the pathogenesis of schizophre-
nia and related mental disorders, we sought in the present
study to identify and analyze the BRD1 interaction net-
work, encompassing BRD1-S and BRD1-L protein-protein
interactions (PPIs) and chromatin interactions as well as
genes being regulated upon up- or downregulation of
BRD1. Moreover, we interrogated large GWAS datasets




The generation of cell lines stably expressing BRD1-S-V5
and BRD1-L-V5 have previously been described [9].
HEK293T cells (controls and stable BRD1-S-V5 and
BRD1-L-V5 cell lines) were grown in DMEM medium
(Invitrogen, San Diego, CA, USA) supplemented with 5 %
fetal calf serum (FCS), 175 mg/L glutamine, 36 mg/L peni-
cillin, and 60 mg/L streptomycine at 37 °C in 5 % CO2.
Co-immunoprecipitation (Co-IP)
Preparation of cell extract was performed according to
the two-step procedure described in [12]. Experiments
were carried out in 10 cm or 15 cm petri dishes with
1 × 107 cells or 2 × 107 cells plated, respectively. 1 × 108
cells were used for each immunoprecipitation (IP). Cells
were counted using a Nucleocounter (ChemoMetec A/S,
Alleroed, Denmark) and plated 24 h before harvested
using 1 mL per 10 × 106 cells hypotonic Triton X-100
lysis buffer (20 mM Tris–HCl [pH 7.4], 10 mM KaCl,
10 mM MgCl2, 2 mM EDTA, 10 % glycerol, 1 % Triton
X-100, 2.5 mM β-glycerophosphate, 1 mM NaF, 1 mM
DTT+ protease inhibitors (Roche, Mannheim, Germany])
for 10 min on ice. Cell lysate was distributed to 15 mL
tubes with 2 mL in each for sonication. DNA was frag-
mented by sonication (Bioruptor, settings: on 0.5, off 0.5)
for 15 min at 6 °C. A total of 5 M NaCl was added to a
final concentration of 420 mM, mixed and incubated on
ice for 15 min after which the DNA fragmentation was re-
peated. Sonicated cell lysate was then cleared by centrifu-
gation at maximum speed for 15 min and the supernatant
was recovered for IP.
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IP of V5 epitope tagged proteins was performed as
follows: Anti-V5 and anti-HA antibody conjugated
agarose beads (Sigma Aldrich, Steinheim, Germany)
were washed twice in PBS before use and blocked in 1 %
BSA. Cell lysates were pre-cleared for 30 min at 4 °C
under rotation using 30 μL anti-HA antibody conjugated
bead solution before collecting the supernatant (400 rpm
for 5 min) for IP. IP was performed using 60 μL of the
bead solution per 10 mL lysate. Beads were added to the
pre-cleared supernatant and incubated at 4 °C overnight
before they were collected at 400 rpm for 15 min. Beads
were washed twice in 10 mL Triton X-100 buffer 250
(20 mM Tris–HCl [pH 7.4], 250 mM NaCl, 10 mM
MgCl2, 2 mM EDTA, 10 % glycerol, 1 % Triton X-100,
2.5 mM β-glycerophosphate, 1 mM NaF, 1 mM DTT, pro-
tease inhibitors [Roche]) then moved to Protein LoBind
tubes (Eppendorf, Hamburg, Germany) and then washed
six times in Triton X-100 buffer 150 (20 mM Tris–HCl
[pH 7.4], 150 mM NaCl, 10 mM MgCl2, 2 mM EDTA,
10 % glycerol, 1 % Triton X-100, 2.5 mM β-
glycerophosphate,1 mM NaF, 1 mM DTT, protease inhibi-
tors [Roche]). Proteins were eluted in 100 μL Elution
buffer (HENG) (10 mM HEPES-KOH [pH 9.0], 1.5 mM
MgCl2, 0.25 mM EDTA, 20 % glycerol, 250 mM KCl,
0.3 % NP40 + 0.5 mg/mL V5 peptide [Sigma], protease
inhibitors [Roche]). Cell lysate was kept cold at all times,
between 1 °C and 6 °C. The process was carried out in one
continuous procedure without any freezing/thawing of the
cell lysate. IP with anti-V5 antibody and IP with anti-HA
antibody was performed four times with either extracts
from HEK293T, stable BRD1-S-V5, or BRD1-L-V5
expressing cell lines, adding to a total of 24 IP samples
prepared for mass spectrometry.
IP of endogenous PBRM1 was performed using the
same procedure as described above. Protein A and G
beads (GE Healthcare, Uppsala, Sweden) were washed
twice in PBS and blocked in 1 % BSA (final concentration).
Pre-clearing and IP was performed in a 50/50 μL mix of
blocked protein A and G bead solutions. A total of 30 μL
of protein A and G bead solution was used for preclearing
of cell extracts and 60 μL of protein A and G bead
solution was used for IP. Anti-PBRM1 antibody (Cat.
no. A301-590A, Bethyl, Montgomery, AL, USA) was
diluted in Triton X-100 buffer 150 according to antibody
specifications and incubated with blocked protein A and
G bead solution at 4 °C overnight. IP control reactions
were performed in parallel by the same method but with-
out the addition of antibody. Furthermore, elution was
performed with 1 % SDS instead of the V5 peptide solu-
tion as described above.
Sample preparation for mass spectrometry
Proteins eluted upon IP were precipitated in six volumes
of acetone (–20 °C), incubated at –20 °C overnight, and
centrifuged at 15,000 × g at 4 °C. The supernatant was cau-
tiously removed and the protein pellet was carefully
washed in ice-cold 90 % acetone, centrifuged at 15,000 g
and air-dried. Disulfide bonds of the proteins were reduced
in 90 μL buffer containing 50 mM tris-(2-carboxyethyl)-
phosphine (TCEP) (Sigma Aldrich, Steinheim, Germany)
and 50 mM ammonium bicarbonate, and incubated at
60 °C for 10 min. The reduced cystein residues were
blocked by 50 mM of the alkylation agent iodoacetamide
(Sigma-Aldrich, Steinheim, Germany). Proteins were
digested into peptides by addition of 1 μg trypsin (Trypsin
Gold from Promega, Madison, WI, USA) in 100 μL
50 mM ammonium bicarbonate.
Mass spectrometry analysis
The peptide mixtures were analyzed by nanoliquid chroma-
tography (Easy nLC from Proxeon, Denmark) coupled to
mass spectrometry (MS) (Thermo Fisher, LTQ-Orbitrap),
with separation on a reverse phase column (75 μm,
100 mm, and 3.5 μm C18 particles) at a flow rate of
300 nL/min using a 100 min gradient (5–35 %) of aceto-
nitrile in 0.4 % acetic acid. The MS detection constituted a
full scan (m/z 400 − 2000) in Orbitrap (<3 ppm mass ac-
curacy) followed by up to four data dependent MS/MS
fragmentation scans using collision induced dissociation
(CID).
Database searches and MS statistics
The resulting MS files were processed essentially as pre-
viously described [13]. Briefly, Mascot version 2.2.04
(Matrix Science) was used for peptide identification and
MaxQuant version 1.0.13.18 for protein identification
and label-free quantification [14]. The MS data were
searched against IPI protein database version 3.52 con-
taining 73,928 sequences and the same number of re-
versed sequences for false discovery rate calculations
(FDR). FDR was set to 0.01 for both identification of
peptides and proteins. MS/MS mass tolerance was
5 ppm for peptide masses and 0.5 Da for fragment
masses. Setting of trypsin digestion was cleavage at
C-terminus of lysine and arginine except before proline
and up to two missed cleavages were accepted. Carba-
midomethylation at cysteine residues was set as fixed
modification and oxidation of methionine was set as vari-
able modification. Only peptides with a minimum length
of six amino acid residues were accepted and at least two
peptides (and one unique peptide) were required for pro-
tein identification.
Proteomics data analysis
The combined spectral intensity of each individual pro-
tein was normalized to the mean intensity of all the pro-
teins for each sample or control. Intensities below the
detection limit were assigned the value of mean of the
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minimum intensities from across all datasets, and then
normalized with the mean intensity of all values in the
sample or control. Extracts from stable BRD1-S-V5 and
BRD1-L-V5 expressing cells and from HEK293T cells
were used in co-IP experiments. Each co-IP experiment
was performed four times followed by LC-MS/MS ana-
lysis, using beads with anti-V5 conjugated antibody
(IP:V5) or anti-HA conjugated antibody (IP:HA) and
extracts from stable BRD1-S-V5, BRD1-L-V5 ex-
pressing cells, or HEK293T cells, yielding: (4 × IP:V5
4 × BRD1-S-V5, 4 × IP:HA BRD1-S-V5, 4 × IP:V5 BRD1-L-
V5, 4 × IP:HA BRD1-L-V5, 4 × IP:V5 HEK293T, 4 × IP:HA
HEK293T). Four criteria (1–4) were raised to systematically
identify repeatedly co-immunoprecipitated (co-IPed) pro-
teins by calculating the enrichment ratio (log2 (sample) –
log2 (control)), where control experiment is IP without
proper BRD1 in the sample or without antibody against
the proper BRD1 construct. The four criteria were: (1) the
enrichment ratio IP:V5 BRD1-(S or L)-V5 - IP:HA BRD1-
(S or L)-V5 of a protein is > cutoff value; (2) the enrich-
ment ratio IP:V5 BRD1-(S or L)-V5 - IP:V5 HEK293T of a
protein is > cutoff value; (3) the enrichment ratio IP:V5
BRD1-(S or L)-V5 - IP:HA HEK293T of a protein is > cut-
off value; (4) the enrichment ratio IP:V5 BRD1-(S or L)-
V5 - the mean of all controls of a protein is > cutoff value.
Both two- and threefold cutoffs were applied to sort the
identified protein-protein interactions according to co-IP
strength (Table 1).
Western blotting
Protein samples were prepared for SDS-PAGE using
5× loading buffer and 20× reducing agent (Fermentas,
St. Leon-Rot, Germany) and then placed in a heating
block for 5 min at 100 °C. Denatured proteins were loaded
onto TGX or Tris-HCL 4–15 % linear gradient polyacryl-
amide gels (Bio-Rad Laboratories) and separated by elec-
trophoresis at 100–120 V. Proteins were transferred to
Hybond-P Membranes (GE Healthcare, Uppsala, Sweden)
using a wet blotting apparatus (Bio-Rad Laboratories).
Membranes were activated in 99 % alcohol for 20 s,
washed in redistilled water for 1 min, and transferred to
transfer buffer (Tris 50 mM Tris, 385 mM glycine, 7 mM
SDS, 10 % Ethanol). Membranes were blocked for 1 h in
blocking buffer (10 % skimmed milk powder, 1 % Tween
20, and PBS). Primary antibodies were: monoclonal anti-
V5 antibody (Invitrogen, R960-25) diluted 1:2000 in wash
buffer (0.05 % Skimmed milk powder, 0.005 % Tween 20,
and PBS) and anti-BRD1 antibody (65/66 Sigma Genosys),
previously described [9]. Secondary antibodies were: HRP
conjugated anti-mouse IgG antibody (Dako Cytomation,
P0447, Glostrup, Denmark) and HRP conjugated anti-
rabbit IgG antibody (Dako Cytomation, P0448, Glostrup,
Denmark). Dilutions were according to the manufacturer’s
protocol. All incubations were performed in 5–10 mL
wash buffer. Membranes were incubated with primary
antibodies for 24 h at 4 °C, followed by 3× 5 min wash
and for 1 h with secondary antibody at 4 °C and washed
5× 5 min with wash buffer. Immunoreactivity was de-
tected using BM Chemoluminescence substrate (POD)
(Roche Applied Science, Mannheim, Germany) according
to the manufacturer’s protocol and the Image Reader
LAS-3000 v2.2 program (Fujifilm, Minato (Tokio), Japan).
Densitometric analysis was performed with the Multi
Gauge v3.1 software (Fujifilm, Minato (Tokio), Japan).
Immunofluorescence
HEK293T cells stably expressing BRD1-S and BRD1-L
and untransfected HEK293T cells were cultured for 48 h
in 10 cm2 slideflasks. Cells were fixed in 4 % freshly
prepared paraformaldehyde, 0.1 % gluteraldehyde, 0.1 %
Trition X-100 solution on ice for 30 min, followed by
wash with PBS for 5 min. Slides were incubated with
anti-V5 antibody (Invitrogen) for 1 h at 4 °C using a
1:200 dilution in PBS and washed 3× 5 min with PBS
containing 0.1 % Triton X-100. Incubation with anti-
mouse immunoglobulins/FITC F(ab’)2 (Dako, Glostrup,
Denmark) was performed for 1 h at 4 °C using a 1:200 di-
lution in PBS supplemented with 5 % FCS. Cell nuclei
were stained by Hoechst staining (Hoechst stain 1 μg/mL)
for 10 min, slides were then washed 2× 5 min in PBS
containing 1 % Triton X-100 and dried. Two drops of
fluorescent mounting media were added to the fixed cells
and stored in the dark at 4 °C until media were dried
out and then viewed under a fluorescent microscope
(Additional file 1).
Chromatin immunoprecipitation (ChIP)
ChIP of V5 epitope proteins were carried out as de-
scribed in [15] with a few adjustments. Eight million
cells per reaction were seeded 24 h before use in 10 mL
medium. Formaldehyde, to the final concentration of
1 %, was added directly to the cell medium, on a shaker.
The cross-linking reaction was stopped after 10 min by
addition of glycine to the final concentration of 0.125 M,
on a shaker. Cells were carefully washed twice in 10 mL
cold PBS, harvested in 1 mL ChIP dilution buffer
(0.01 % SDS, 1.1 % Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCL, 167 mM NaCl) and protease inhibi-
tors (Complete mini, Roche, Mannheim, Germany) and
sonicated on ice (Bioruptor, settings: on 0.5, off 1.0) for
15 min at 6 °C. Cell lysate was cleared by 2 min max-
imum centrifugation at 6 °C. Supernatant was collected
and stored at –80 °C.
Immunoprecipitations were carried out using 20 μL of
anti- V5 or anti- HA conjugated agarose beads (Sigma,
A7345, A2095). First, the beads were washed twice
in PBS and protease inhibitors (Roche, Mannheim,
Germany) with intermediate low g centrifugation. Beads
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Table 1 Summary of BRD1 PPIs identified by co-IP mass spectrometry
Co-IP MS/MS Co-IP strengtha Protein Uniprot ID Gene name Peptide P valueb
BRD1-S 1 BRD1 O95696 Bromodomain-containing protein 1 <1 × 10–10
ZC3H15 Q8WU90 Zinc finger CCCH domain-containing
protein 15
<1 × 10–10
DRG1 Q9Y295 Developmentally regulated
GTP-binding protein 1
<1 × 10–10
C1QBP Q07021 Complement component 1
Q sub-component-binding protein
<1 × 10–10
MYST2 O95251 K(lysine) acetyltransferase 7 <1 × 10–10
SUV420H1 Q4FZB7 Suppressor of variegation 4-20 homolog 1 <1 × 10–10
MEAF6 Q9HAF1 MYST/Esa1-associated factor 6 <1 × 10–10
YWHAE P62258 14-3-3 protein epsilon 5.1 × 10–9
PBRM1 Q86U86 Polybromo-1 2.7 × 10–3
ING4 Q9UNL4 Inhibitor of growth protein 4 4.2 × 10–3
ING5 Q8WYH8 Inhibitor of growth protein 5 1.1 × 10–2
2 NPM1 P06748 Nucleophosmin <1 × 10–10
YWHAZ P63104 14-3-3 protein zeta/delta <1 × 10–10
KPNA1 P52294 Importin subunit alpha-1 <1 × 10–10




YWHAB P31946 14-3-3 protein beta/alpha 1.6 × 10–7
NAP1L4 Q99733 Nucleosome assembly protein 1-like 4 1.6 × 10–7
CLTC Q00610 Clathrin heavy chain 1 2.7 × 10–6
DNMT1 P26358 DNA (cytosine-5)-methyltransferase 1 1.6 × 10–5
LYAR Q9NX58 Cell growth-regulating nucleolar protein 2.1 × 10–5
MRPS14 O60783 28S ribosomal protein S14 5.6 × 10–4
EIF3I Q13347 Eukaryotic translation initiation factor
3 subunit I
5.2 × 10–3
3 PHB2 Q99623 Prohibitin-2 8.4 × 10–7
NSUN2 Q08J23 NOP2/Sun RNA methyltransferase 7.3 × 10–3
BRD1-L 1 BRD1 O95696 Bromodomain-containing protein 1 <1 × 10–10
YWHAE P62258 14-3-3 protein epsilon <1 × 10–10
ZC3H15 Q8WU90 Zinc finger CCCH domain-containing
protein 15
<1 × 10–10
DRG1 Q9Y295 Developmentally regulated
GTP-binding protein 1
<1 × 10–10
YWHAG P61981 14-3-3 protein gamma <1 × 10–10
MEAF6 Q9HAF1 MYST/Esa1-associated factor 6 8.5 × 10–7
ING5 Q8WYH8 Inhibitor of growth protein 5 9.1 × 10–4
PBRM1 Q86U86 Polybromo-1 1.3 × 10–3
MRPS34 O60783 28S ribosomal protein S14 1.5 × 10–3
ING4 Q9UNL4 Inhibitor of growth protein 4 6.2 × 10–3
QSER1 Q2KHR3 Glutamine and serine-rich protein 1 6.4 × 10–3
2 YWHAZ P63104 14-3-3 protein zeta/delta <1 × 10–10
CLTC Q00610 Clathrin heavy chain 1 9.8 × 10–4
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were blocked in 10 × volume PBS, 200 μg/mL sonicated
herring DNA, and 1.5 % BSA at RT and washed in ChIP
dilution buffer. Extracts were pre-cleared with 20 μL of
blocked anti-HA beads at rotation for 30 min before im-
munoprecipitation with blocked anti-V5 and anti-HA
beads over night at 6 °C. Beads were collected by centrifu-
gation and washed twice in low salt buffer (0.1 % SDS, 1 %
Triton-X 100, 2 mM EDTA, 20 mM Tris-HCL, pH 8.1,
150 mM NaCl, and proteinase inhibitors [Roche]), twice
in high buffer (0.1 % SDS 1 % Triton-X 100, 2 mM EDTA,
20 mM Tris-HCL pH 8.1, 500 mM NaCl, and proteinase
inhibitors [Roche, Mannheim, Germany]), once in LiCl
buffer (0.25 M LiCl, 1 % IGEPAL-CA630, 1 % deoxycho-
lixacid sodium salt, 1 mM EDTA, 10 mM Tris-HCl
pH 8.1, and proteinase inhibitors [Roche, Mannheim,
Germany]), and twice in TE buffer. Elution was performed
in 500 μL freshly made elution buffer (1 % SDS, 0.1 M
NaHCO3, H2O). A total of 20 μL of 5 M NaCl was added
to eluates and incubated for 4 h at 65 °C for reversing
cross-links. A total of 10 μL of 5 M EDTA, 20 μL of 1 M
Tris-HCl pH 6.5, and 2 μL of proteinase K (Finnzymes,
F-202S, 20 mg/mL) was added to eluates and incubated
for 1 h at 45 °C. Phenol/chloroform and isopropanol (v/v)
was added, mixed, and centrifuged. A total of 2 μL of
glycogen (Sigma Aldrich, cat. no. G1767) and 0.7 × volume
isopropanol was added to supernatant and incubated at –
20 °C overnight. Precipitated DNA was collected by centri-
fugation at maximum speed for 30 min at 4 °C. Pellet was
carefully washed in 70 % ethanol, air-dried, and dissolved
in 50 μL redistilled water. ChIP DNA concentrations were
measured on a microplate reader (Thermo Fisher,
Flouroskan Ascent FL) by fluorescence of double-
stranded DNA (dsDNA) (Lifetechnologies/Invitrogen,
Qant-iT™ picogreen, cat. no. P7589). All ChIP DNA
was diluted to the same concentration before quanti-
tative real-time PCR.
ChIP sequencing
DNA libraries were prepared using the ChIP-seq DNA
Sample Prep kit (Illumina; IP-102-1001) and sequenced
on a Genome Analyzer IIx. The sequence reads were
aligned to the human genome (hg19), through the
Galaxy project portal [16], using the Illumina Analysis
Pipeline. Sequenced reads were mapped with Bowtie
[17] allowing one mismatch. Peak calling was performed
using the Model-based Analysis of ChIP-Seq v1.4
(MACS) [18], through the Galaxy project portal. Set-
tings: distance = 100; and otherwise standard settings.
Ensemble (GRCh37.p13) known genes and transcripts
were used as reference gene annotations to identify pro-
moter target genes (PTGs).
RNA and complementary DNA from cell culture
Cultured cells were lysed using Qiashredder columns
(Qiagen, Hilden, Germany) and RNA was purified using
the RNAeasy Mini kit (Qiagen) according to the manu-
facturer’s protocol. RNA concentrations were deter-
mined using a NanoDrop 1000 version 3.7.1 (Thermo
Fisher Scientific, Waltham, MA, USA). RNA integrity
was assessed by 1 % agarose gel electrophoresis. A com-
plementary DNA (cDNA) library was generated from
1 μg of RNA using the iScript™ cDNA Synthesis Kit
(Bio-Rad Laboratories, Hercules, CA, USA). All steps
were performed according to the manufacturer’s proto-
col using a mixture of random hexamers and Oligo-dT
primers provided with the kit.
Microarray expression profiling
Microarray (Affymetrix U219) and RNA quality control
was performed at Aros Biotechnology, Skejby. Further
information is provided elsewhere [19, 20]. A threshold
of 1.5 was set for the fold change of microarray probes
(Additional file 2).
Quantitative real-time PCR
Quantitative real-time PCR was performed on the
LightCycler®480 (Roche Applied Science, Mannheim,
Germany) system. A total of 96 or 384 well plates, with a
respective total reaction volume of 10 μL or 5 Μl, were
used, respectively. Fluorescence of dsDNA was determined
by addition of SYBR®Green (Roche Applied Science,
Mannheim, Germany) to the reactions in the concentra-
tion described by the manufacturer. The standard settings
on the LightCycler software were used for excitation and
Table 1 Summary of BRD1 PPIs identified by co-IP mass spectrometry (Continued)
3 H3F3A/HIST1H3/HIST3H3c P84243/P68431/Q16695c Histone H3.3/Histone H3.1/Histone H3.1 tc <1 × 10–10
YWHAH Q04917 14-3-3 protein eta <1 × 10–10
C1QBP Q07021 Complement component 1
Q sub-component-binding protein
<1 × 10–10
RPL22L1 Q6P5R6 60S ribosomal protein L22-like <1 × 10–10
aCo-IP strength, 1: co-IPed 3–4 out of four repeated experiments and sample/control enrichment ratio >3 across four control experiments, 2: co-IPed 3–4 times out
of four repeated experiments and sample/control enrichment ratio >2 across four control experiments, 3: co-IPed two out of four repeated experiments and
sample/control enrichment ratio >3 across four control experiments (for further details see “Methods”)
bCo-IPed proteins were sorted by the peptide P value (MaxQuant software) within each of three settings for co-IP strength
cIdentified peptides were unique to all listed proteins (encoded by more than one genetically related gene)
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detection of fluorescence. Primer3 [21] was used in the
design of primers (MWG Operon, Ebersberg, Germany).
Gene set enrichment analysis
We used publicly available summary statistics from
single-marker GWASs [4, 22–31] considering only vari-
ants outside the broad MHC-region (chr6:25 M-35 M)
[28] and filtered for info score ≥0.8 if available.
Data on schizophrenia, bipolar disorder, anorexia ner-
vosa, autism, MDD, ADHD, and cross-disorders were
accessed and downloaded via the PGC website [32]. Data
on rheumatoid arthritis were downloaded from [33].
Data on coronary artery disease/myocardial infarction
have been contributed by CARDIoGRAMplusC4D in-
vestigators and have been downloaded from [34]. Data
on type 2 diabetes have been contributed by DIAGRAM
and downloaded from [35]. Data on Crohn’s disease have
been contributed by IIBDG and downloaded from [36].
Data on Alzheimer’s were downloaded from [37] –
International Genomics of Alzheimer’s Project (IGAP) is
a large two-stage study based upon GWAS on individ-
uals of European ancestry. In stage 1, IGAP used geno-
typed and imputed data on 7,055,881 single nucleotide
polymorphisms (SNPs) to meta-analyze four previously
published GWAS datasets consisting of 17,008 Alzheimer's
disease cases and 37,154 controls (The European
Alzheimer’s Disease Initiative – EADI; the Alzheimer
Disease Genetics Consortium – ADGC; The Cohorts for
Heart and Aging Research in Genomic Epidemiology
Consortium – CHARGE; The Genetic and Environmental
Risk in AD Consortium – GERAD). In stage 2, 11,632
SNPs were genotyped and tested for association in an
independent set of 8572 Alzheimer’s disease cases and
11,312 controls. Finally, a meta-analysis was performed
combining results from stages 1 and 2. For the risk gene
enrichment analysis, we used MAGMA [38] and de-
fault settings. Genes were annotated using Ensemble
(GRCh37.p13, same reference for identifying BRD1
PTGs). Information about the genetic correlation pattern
in the data (linkage disequilibrium) was obtained using the
1000 Genomes European panel [39]. To assess whether or
not the BRD1 protein network was enriched with de novo
mutations with relevance to autism risk [40, 41] or rare
mutations with relevance to schizophrenia risk [42], we
compared the proportion of mutations in the genes
among cases to controls (obtained from the referenced
studies) using a one-sided binominal test correcting for
the overall ratio of mutations in cases compared to
controls.
Identification of spatiotemporal networks in the
human brain
Human brain transcriptome (RNA-seq) data were ob-
tained from www.brainspan.org [43]. We filtered the
dataset including only genes with coefficient of variance
more than 0.1 thereby removing genes with little or no
information with regards to the spatiotemporal dynam-
ics. Since the BRD1 network contained both protein-
coding and non-protein-coding genes, both types of
genes were included in the analysis yielding 21,396
uniquely identified genes. Data were segregated into 32
spatiotemporal intervals consisting of eight temporal in-
tervals (P1–P8) and four brain regions (R1–R4). Brain
regions (R) were grouped according to transcriptional
similarities based on the hierarchical clustering described
here [44]. Temporal intervals (P) were grouped as follows:
P1 included post-conceptual week (pcw) 8–13 (first
trimester); P2 included 16–26 pcw (second trimester); P3
included 35–37 pcw (third trimester), P4 included 4–10
months; P5 included 1–4 years; P6 included 8–13 years;
P7 included 15–19 years; P8 included 21–40 years.
The fraction of co-expressed genes (correlation coeffi-
cient >0.5) was calculated for each spatiotemporal interval
and each BRD1 sub-network and compared to the back-
ground of genes co-expressed with BRD1 in the entire
dataset. To determine whether or not the fraction of co-
expressed genes was significantly higher than the back-
ground, a one-sided binominal test was performed while
adjusting the P value for the number of tests performed
(Bonferroni correction).
Software and statistical analysis
Ingenuity Pathway analysis was used for the bioinformat-
ics analysis. Simulations, statistical analysis, and graph-
ical illustrations were conducted in R, Python, Excel
(Microsoft, Office 2010, USA), and GraphPad Prism 5.
Availability of data
The ChIPseq and microarray data discussed in this publica-
tion have been deposited in NCBI's Gene Expression
Omnibus [45] and are accessible through GEO Series ac-
cession numbers GSE62811 (https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE62811) and GSE79255 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79255).
The protein-protein interactions from this publication
have been submitted to the IMEx consortium [46, 47]
through IntAct [48] and assigned the identifier IM-24990.
Results
Identification of BRD1 protein-protein interactions
In order to identify PPIs of the two BRD1 isoforms
(BRD1-S and BRD1-L), we generated HEK293T cells
stably expressing either V5 epitope tagged BRD1-S or
BRD1-L (referred to as BRD1-S and BRD1-L cells). Both
epitope tagged BRD1 isoforms localized to the nucleus
of the HEK293T cells (Additional file 1), suggesting that
the V5 epitope does not disrupt nuclear localization of
the proteins. By co-immunoprecipitations, followed by
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identification of associated proteins using nanoLC
coupled to a LTQ Orbitrap MS/MS system (Fig. 1a–c),
we identified 24 and 16 PPIs for BRD1-S and BRD1-L,
respectively (Table 1). The previously reported BRD1
interaction partners MEAF6, ING4, and ING5 [7, 49] were
identified to interact with both BRD1-S and BRD1-L,
whereas MYST2 [7] was found to interact solely with
BRD1-S (Fig. 1d and Table 1). Likewise, our finding that
histone H3 interacts with BRD1-L (Table 1) is in line with
a previous study that identified the unmodified N-tail of
histone H3 to interact with the PHD1 domain of BRD1
[50]. We cross-referenced the identified protein networks
with public databases (BioGRID, CCSB Human Inter-
action Network Database, DIP, HPRD, IntAct, MINT,
BIND, MPPI, and GNP) and discovered 20 novel BRD1-S
PPIs and 13 novel BRD1-L PPIs which have not previously
been reported, some of which were identified solely for
one isoform (Fig. 1d and Table 1). A recent large-scale
protein-protein interaction study found that the majority
of protein isoforms share less than 50 % of their inter-
action partners [51]. In line with these results, 62.5 % of
the identified PPIs were found to be common among the
two BRD1 isoforms. As an example, the Histone-lysine N-
methyltransferase protein suppressor of variegation 4-20
homologue 1 (SUV420H1) was identified as a specific PPI
for BRD1-S (Fig. 1d and Table 1). As part of the list of
common BRD1 PPIs (i.e. interacting with both BRD1-S
and BRD1-L), we identified the 14-3-3 tyrosine monooxy-
genase proteins YWHAE, YWHAH, YWHAZ, and the
poly bromo 1, PBRM1 (Table 1). These PPIs are of
particular interest since genetic association studies have
previously implicated YWHAE, YWHAH, and YWHAZ
with schizophrenia and bipolar disorder [52–55] and
the PBRM1 locus has surpassed genome-wide sig-
nificance in both schizophrenia and bipolar disorder
GWASs [4, 56–58]. We confirmed the interaction be-
tween BRD1 (for both isoforms) and PBRM1, by co-IP
with antibodies against endogenous PBRM1 followed by
western blot detection of BRD1 (Additional file 3).
Identification of chromatin-binding sites of BRD1 by ChIP
sequencing
To identify BRD1 chromatin interactions and target
genes, we conducted chromatin immunoprecipitation of
epitope tagged BRD1-S and BRD1-L from the cell lines
described above (Additional file 4) followed by next gen-
eration DNA sequencing (ChIP-seq) generating on
average 24 million mapped reads (Additional file 5). We
identified 2205 and 1722 ChIP-seq peaks for BRD1-S
and BRD1-L, respectively. The identified peaks inter-
sected more with promoter regions (defined as the re-
gion from a transcription start site and 5 kb upstream),
transcribed regions (all exons, introns, and UTRs), exons
(all exons), 5’UTR, and exon 1 of protein-coding genes
compared to random genomic regions of the same sizes
and chromosome distributions (Fig. 2a). This was not
observed for 3’UTR regions and exon 2, providing evi-
dence that the increased intersection with transcribed
regions, is caused by frequent intersections with 5’UTR
and/or exon 1 regions (Fig. 2a). Furthermore, BRD1-S
and BRD1-L peaks were predominantly located near
transcription start sites (TSSs) of genes (Fig. 2b, left
panel). In order to gain more insights as to where
BRD1-S and BRD1-L primarily bind at TSSs, we counted
the number of sequencing reads obtained from the
ChIP-seq data across a window of +/– 5 kb from TSS
for all protein-coding genes in the human genome. This
approach showed that the majority of sequencing reads
aligned upstream (0 to –2 kb) from TSS of genes while
another, smaller part of the reads aligned downstream
(0 to 2 kb) from TSS of genes (Fig. 2c) suggesting that
BRD1-S and BRD1-L bind mainly upstream but also
downstream of TSS of genes. To further investigate
whether BRD1 binds in a co-occurring manner at TSSs,
we generated a heatmap of BRD1-S ChIP-seq read
counts in TSSs from chromosome 1 and 10 (Fig. 2d).
The analysis did not indicate that BRD1 binding was
occurring twice at the same TSS. To evaluate the func-
tional role of BRD1-S and BRD1-L, we compared all
ChIP-seq regions to ChIP-seq regions of histone marks
[59] and other chromatin binding proteins [60] and
generated genomic binding profiles for both isoforms
(Fig. 2e and Additional file 6). Both BRD1-S and BRD1-
L were found to bind regions that highly overlap with
histone H3K9ac genomic regions. Interestingly, the his-
tone H3K9ac level was previously found to be reduced
in erythroblasts (CD71+ Ter119–) isolated from Brd1–/–
mouse embryos [7]. Furthermore, large subsets of
BRD1-S and BRD1-L ChIP-seq regions were found in
close proximity of or directly overlapping with RNA
polymerase II binding sites (Fig. 2b, right panel and E).
In view of the aforementioned results, predominant
binding at RNA polymerase II binding sites, histone
H3K9ac sites, promoter regions, 5’UTR, exon 1, and
TSSs suggest that BRD1 primarily binds to actively
transcribed regions of the genome. We observed a sub-
stantial proportion of the BRD1-S and BRD1-L peaks to
be located at bi-directional/head-to-head genes that
may share promoter or enhancer elements. Binding of
BRD1 at these sites potentially affects transcription of
both genes. Consequently, we defined BRD1 PTGs as
genes having TSS within a window of +/– 5 kb from a
BRD1 ChIP-seq peak. Overall, we identified sets of
1540 and 823 PTGs for BRD1-S and BRD1-L, respect-
ively, with 251 PTGs being common to both isoforms
(Fig. 2f ). Among these, we validated five by ChIP
followed by quantitative real-time PCR (Additional file 7
and Additional file 8).
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Fig. 1 Co-immunoprecipitation (co-IP) coupled to mass spectrometry MS/MS analysis of BRD1-S and BRD1-L. a co-IPs were performed on cell
extracts harvested from BRD1-S, BRD1-L, and HEK293T cell lines, using either anti-V5 antibody conjugated (IP-V5) or anti-HA antibody conjugated
(IP-HA) beads. Cell culturing, extract preparation, and co-IP were repeated four times before preparation for mass spectrometry analysis (for further
details, see “Methods”). b, c The combined spectral intensity of each individual protein was normalized to the mean intensity of all the proteins for
each sample or control. In total, 319 proteins were identified from at least one sample or control in the analysis. The plots represent the normalized
(Log2) spectral intensities of each identified protein (black) plotted as sample (y-axis) against control (x-axis). BRD1 (blue) was identified as the most
enriched protein in the BRD1-S (b) and BRD1-L (c) pull-downs. The plots, from the upper right to the lower left, illustrate a stepwise sorting of proteins
that showed > two- or > threefold enrichment (red and orange, respectively, and otherwise black) in the sample compared to controls. The last plots
in (b) and (c) show the proteins that were identified as enriched in all controls, where the x-axis represents the mean of all the control experiments.
These proteins were then further divided into three levels of co-IP strength taking into account the reproducibility of the co-IP within the repeated
experiments (see Table 1). d BRD1 PPI network. Gray lines represent the interactions identified in this study by co-IP LC-MS/MS and black lines represent
experimentally verified PPIs annotated in publicly available databases (BioGRID, CCSB Human Interaction Network Database, DIP, HPRD, IntAct, MINT,
BIND, MPPI, and GNP). A high level of red in nodes indicates a high number of edges while a high level of blue indicates a low number of edges
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Fig. 2 ChIP sequencing analysis of BRD1-S and BRD1-L. a The percentages of BRD1-S and BRD1-L ChIPseq peaks that intersect promoter regions of
protein-coding genes (defined as 5 kb upstream from transcription start site), transcribed regions (all exons, introns, and UTRs), exons (all exons), 5’UTR,
exon 1 exon 2, and 3’UTR, were identified and shown by the perforated blue and green lines in the graph. Random peak regions, comprising the same
chromosome distribution and region sizes as the BRD1 ChIPseq regions, were generated and shown as Random 1 (2205 regions, red) and Random 2
(1722 regions, gray). b The minimum relative distance from a BRD1-S and BRD1-L ChIP-seq region to transcription start sites (left panel) or to RNA Pol II
binding sites (right panel) was identified for all 2205 (BRD1-S) and 1722 (BRD1-L) regions and illustrated as the blue histograms. Random peak regions
comprising the same chromosome distribution and region sizes as the BRD1 ChIPseq regions were generated and shown as red line histograms
(Random). c In order to generate a profile of BRD1-S (blue), BRD1-L (green) binding to the TSS of genes, we identified and plotted the number of
sequenced reads per total reads across a window of +/– 5 kb from the TSS of all protein-coding genes in the human genome. The control (Ctrl, black)
represents ChIP-seq using an antibody against the HA-epitope. d A heatmap of read counts from BRD1-S ChIP-seq across a +/– 2.5 kb window from
the TSS of genes located on chromosome 1 and 10. Only regions with high read counts are shown here. e ChIPseq regions of chromatin-binding
proteins and histone marks, identified in HEK293 cell lines, were obtained from the ENCODE database and from a histone H3K9ac dataset [59]. The
percentages of BRD1-S and BRD1-L ChIPseq peak regions that intersected with the binding of other chromatin-binding proteins or the location of
histone marks were identified and illustrated as heatmaps. f Genes comprising transcription start sites in a window of +/– 5 kb from a BRD1-S or BRD1-L
ChIP-seq peak region were identified as promoter target genes (PTGs). Venn diagram illustrates the number of PTGs identified for BRD1-S and BRD1-L
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Pathway analysis of the BRD1 interaction network
To further characterize the identified BRD1 interaction
network, we used the Ingenuity Pathway Analysis (IPA)
software to identify enrichment of specific pathways.
Three datasets (BRD1-S PTGs + PPIs, BRD1-L PTGs +
PPIs, and the combined BRD1 PTGs + PPIs) were ana-
lyzed according to gene categories (diseases and disor-
ders, molecular and cellular functions, and physiological
system development functions) and pathways as defined
by IPA. After correction for multiple testing, we identi-
fied two, one, and 21 significant IPA categories, as well
as, 14, six, and 27 significant canonical pathways among
the three tested BRD1 interaction networks, respectively
(categories, pathways, and genes within these can be
found in Additional file 9). The most significant category
in all three BRD1 interaction networks was the gene-
expression category. Of neuropsychiatric relevance, we
identified the abnormal morphology of neural arch and
malformation of brain as significant sub-categories when
analyzing the full set of BRD1 PTGs + PPIs. The most
significant pathways identified for the subsets of BRD1-S
and BRD1-L were IGF-1 Signaling and Cell Cycle: G1/S
Checkpoint Regulation, respectively. Together the re-
sults indicate that BRD1 is a regulator of transcriptional
processes and that it is involved in pathways important
for brain development.
Identifying differentially expressed genes following
changes in BRD1 expression levels
To identify differentially expressed genes following ex-
pression level changes in BRD1, we extracted RNA from
BRD1-S and BRD1-L cells and parental HEK293T cells
(Additional file 10) as well as from HEK293T cells trans-
fected with siRNA directed against BRD1 or scrambled
siRNA (Additional file 11). Microarray expression ana-
lyses covering 17,051 genes were performed on cDNA
libraries constructed from the RNA samples (Additional
file 2). Combining the results from both BRD1 up- and
downregulation studies yielded a list of 4643 differen-
tially expressed genes (DEGs), defined as having a probe
fold change of more than 1.5, and corresponding to
27 % of the genes covered by the microarray. We subse-
quently examined whether the identified DEGs were
enriched within BRD1 PTGs. For both BRD1-S and
BRD1-L, DEGs accounted for 33 % of all PTGs, which
represents a significant enrichment (P <0.001; Additional
file 12). The observed enrichment supports that BRD1
binding at TSSs takes part in regulating gene expression.
Exploring the gene-regulatory potential of BRD1-S and
BRD1-L isoforms
In order to explore the gene-regulatory potential of
BRD1-S and BRD1-L isoforms, we performed integrative
analyses of ChIP-seq and gene expression data. The
number of up- and downregulated DEGs according to
expression level from each study (BRD1-S or BRD1-L
upregulation or BRD1 siRNA-mediated downregulation)
is illustrated in Fig. 3a–d. Also, we investigated the over-
lap of DEGs identified after upregulating either BRD1-S
or BRD1-L (Fig. 3e). We then created a window in-
cluding +/– 200 kb from each BRD1 binding site, frag-
mented the window in 10 kb segments, and determined
the number of DEGs having TSSs in these segments.
The analysis was performed for DEGs identified after
upregulating BRD1-S or BRD1-L or downregulating en-
dogenous BRD1 (Fig. 3f, g, Additional file 13). Signifi-
cantly more up- or downregulated genes were identified
in segments where BRD1-S or BRD1-L binds in close
proximity to TSSs compared to all segments across the
window (P <0.001) supporting that BRD1-S and BRD1-L
are involved in regulating expression of genes when
bound in close proximity to the TSSs. Within these seg-
ments, upregulation of either BRD1-S or BRD1-L re-
sulted in more upregulated compared to downregulated
genes while downregulating BRD1 resulted in more
downregulated compared to upregulated genes. Further-
more, upregulation of BRD1-L proportionally generated
more downregulated genes compared to BRD1-S in
these segments (Fig. 3f, g). We conclude that both
BRD1-S and BRD1-L primarily play a role in activation
of gene expression when bound near TSSs, although
they may act, and BRD1-L in particular, as a repressor
for a subset of genes. Interestingly, for BRD1-L upregu-
lated DEGs we observed the additional feature that in-
creased expression fold changes were present when
having the TSS either –50 kb upstream or 100 kb down-
stream the BRD1-L binding site (Fig. 3g). This suggests
that BRD1-L may also participate in activating gene ex-
pression distal from its binding sites.
In order to investigate BRD1 gene-regulatory poten-
tial while considering all genes on the array (and not
only DEGs), we segmented and calculated the average
fold change of all probes within windows +/– 10 kb
and +/– 200 kb from BRD1 binding sites similarly as in
the previous analysis. Overexpressing BRD1-S primarily
increased the overall expression fold change of genes with
BRD1-S binding approximately +/– 1 kb from their TSSs
while downregulating BRD1 reversibly downregulated
genes within the same range (Additional file 13). Overex-
pressing BRD1-L resulted in increased expression of genes
having TSSs –50 kb upstream and +100 kb downstream
of BRD1-L binding similar to what we observed in the
previous analysis of the DEGs; however, a clear reverse
pattern was not observed after downregulating BRD1
(Additional file 13).
The integrative analysis of ChIP-seq and gene expres-
sion data collectively suggests that BRD1 can activate
and more rarely, repress, gene expression by binding to
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TSSs, as well as suggesting that specifically the BRD1-L
isoform plays a role in activating gene-expression distal
from its chromatin binding sites.
Pathway analysis of DEGs identified as a consequence of
upregulating BRD1-S and BRD1-L
To elucidate potential functional consequences of the
BRD1-mediated changes in gene expression and identify
potential differences between BRD1-S and BRD1-L iso-
forms, the DEGs identified by upregulating either BRD1-S
or BRD1-L were analyzed by IPA software to identify
enrichment of specific canonical pathways. DEGs were
defined as previously stated using a 1.5 threshold on the
probe fold change. The top ten most significant canonical
pathways can be found in Additional file 14. The genes in
all the pathways were mainly upregulated. The most sig-
nificant canonical pathway identified when upregulating
BRD1-S or BRD1-L was Reelin Signaling in Neurons and
IL-8 Signaling, respectively. Of notice, the IGF1 Signaling
pathway which was identified to be the most significant
pathway among the BRD1-S interaction network was also
identified among the ten most significant pathways of the
BRD1-S DEGs further implicating BRD1-S with IGF1
signaling. Among the identified pathways, the Reelin
Signaling in Neurons pathway is of a particular interest to
brain function and development [61].
Fig. 3 Integration of ChIP-seq data and gene-expression data. a Examples of gene expression arrays performed. Shows (a) upregulation of BRD1-S vs.
control, (b) upregulation of BRD1-L vs. control, (c) siRNA downregulation of BRD1 vs. control, and (d) two controls transfected with scrambled siRNA,
control 1 vs. control 2. The red lines indicate fold change 1.5 which was used in this study to identify DEGs. The number of upregulated
and downregulated DEGs is shown for each study in the upper left and lower right corner, respectively. Three siRNA knockdown experiments of BRD1
(KD1-3) were performed. More information about KD1-3 can be found in Additional file 10. e The number of genes that overlap after upregulating
BRD1-S and BRD1-L expression. After upregulating either BRD1-S or BRD1-L, the number of DEGs was identified in 10 kb segments (blue bars) across
a window of +/– 200 kb from either (f) BRD1-S or (g) BRD1-L binding sites, respectively. The expression fold change quartiles were obtained from
segments of 10 DEGs. Gray areas indicate the upper and lower quartiles while the middle is shown as a gray line
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Correlation of the BRD1 interaction network with
spatiotemporal BRD1 expression profiles in the
human brain
In order to explore the role of BRD1 in the human brain,
we obtained temporal RNA-seq profiles and expression
array profiles from the Brainspan atlas of the developing
human brain [43] and the Human Brain Transcriptome
database [62], respectively. A high BRD1 expression was
observed in the fetal stages (until approximately day
180) for all brain regions whereas a high BRD1 expres-
sion in the cerebellar cortex was observed throughout
the timeline of the datasets (age >40 years; Additional
file 15). To investigate whether the identified BRD1 inter-
action network is likely to operate in the context of the
human brain, we used data from the Brainspan RNA-seq
database to correlate the expression of 21,906 genes with
BRD1 expression across 13 developmental stages and 26
different brain regions in the human brain. Correlation
values (Fig. 4a) for all genes ranged from 1 (complete
correlation with BRD1 expression) to –1 (complete anti-
correlation with BRD1 expression). In total, 1241 and 672
interaction partners (PTGs + PPIs) for BRD1-S and BRD1-
L, respectively, were identified in the Brainspan database
(Fig. 4b). We observed significantly more correlation for
both of the BRD1 isoforms than expected by chance
(Fig. 4c), indicating that the BRD1 interactions are likely
to occur also in the human brain. The PPIs identified for
BRD1-S and BRD1-L were also more correlated with BRD1
expression (P <1 × 10–10 and P = 0.0039, respectively); in
particular, SUV420H1, DNMT1, PBRM1, and CHD4 were
highly correlated with BRD1 (Fig. 4d).
Disease risk enrichment analysis of the BRD1 interaction
network
Using available GWAS datasets obtained from the
Psychiatric Genomics Consortium (PGC) we investi-
gated whether the BRD1 interaction network is enriched
for mental disorder risk applying the MAGMA program
[38]. As the evidence for genetic association to the
BRD1 locus is particularly strong in schizophrenia, we
tested for enrichment in this disorder as our main
analysis. Out of the entire BRD1 network, 1853 genes
Fig. 4 Co-expression analysis of the BRD1 interaction network in human brain. a A total of 21,906 gene-correlation values ranging from 1 to –1
were obtained across 13 developmental stages and 26 different brain regions from the Brainspan RNA-seq database. Correlation values for all
genes were illustrated as a blue line and gray and white bins (#1–4) define sections (1 to 0.5, 0.5 to 0, 0 to –0.5, and –0.5 to -1) where the number
of genes in each bin was shown at the top. b From the identified BRD1-S and BRD1-L PTGs + PPIs, 1241 and 672 were identified in the database,
respectively. The correlation values for each gene distribute into bins #1–4 as illustrated. c The distributions of the correlation values of all genes in the
Brainspan database and the correlation values of BRD1-S and BRD1-L PTGs + PPIs (BRD1-S and BRD1-L interaction networks) were summarized as
relative to the number of genes and illustrated in a histogram (a.u. = arbitrary units). Mann–Whitney tests were performed for correlation values from
either of the BRD1-S or BRD1-L interaction networks and all genes identified. Both tests resulted in the rejection of the null hypothesis of identical
medians (P < 1 × 10–10). d Correlation values for the BRD1 PPIs represent the level of co-expression with BRD1 in the developing human brain
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remained after filtering SNPs and removing genes in the
MHC region (see Methods), 468 of these had gene-wide
P values <0.05, and 44 of these were significant after
adjusting for the number of genes tested (Additional
file 16). In this analysis the entire BRD1 network
showed significant enrichment (Fig. 5).
In order to explore whether the interaction network
might also be enriched for susceptibility to other mental
disorders, we tested 12 other GWAS datasets, compris-
ing eight psychiatric disorders and four disorders not
considered related to brain function. In addition, to
investigate whether the risk enrichment is dependent on
the specific isoform, we stratified for BRD1-S and BRD1-
L sub-networks. When adjusting for the number of
GWASs tested, significant enrichment was observed
solely for the entire BRD1 network in schizophrenia
(Padjusted = 0.03, Fig. 5). Interestingly, substantial differ-
ences in enrichment patterns between the two BRD1 iso-
forms were observed in several disorders. The BRD1-S
sub-networks comprising PTGs showed enrichment for
schizophrenia and anorexia nervosa while the PPI sub-
network showed evidence of enrichment for attention def-
icit hyperactivity disorder (ADHD) and major depressive
disorder (MDD) risk before adjusting for the number of
tests (P <0.05). These results suggest that the BRD1-S net-
work may play a larger role in mental disorder risk com-
pared to the BRD1-L network.
Finally, we explored whether the network was enriched
for de novo mutations and rare disruptive variants ob-
served in autism and schizophrenia [40–42]. The ana-
lysis did not identify significant enrichment. However, in
particular among the PPI network genes, we did observe
de novo mutations in autism probands that were not
identified in healthy siblings, including one missense
mutation in BRD1, one missense mutation in CHD4, and
four disruptive and two missense mutations in SUV420H1
[40, 41], as well as rare disruptive mutations seen only in
schizophrenia cases and not in controls (in BRD1, ING5,
YWHAZ, NAP1L4, MYST2, and HIST1H3A) [42].
In summary, we identify the BRD1 interaction network
to be enriched for schizophrenia risk thereby providing
supporting evidence that BRD1 plays a role in the etiology
of schizophrenia. Additionally, our analyses suggest that
the BRD1-S interaction network is more enriched for
mental disorder risk, including schizophrenia risk, com-
pared to the interaction network of BRD1-L.
Exploring the BRD1 spatiotemporal interaction networks
in the human brain
Taking into consideration that the BRD1 network is
enriched with schizophrenia risk and that this enrich-
ment seems to be more pronounced in the BRD1-S net-
work, we asked whether these networks are more likely
to be interacting in specific regions and developmental
intervals in the human brain. In order to evaluate co-
expression with BRD1 in the human brain, we applied
an approach similar to the one described here [63]. We
used RNA-seq data from Brainspan to build 32 spatio-
temporal intervals comprising eight temporal intervals
(P1–P8) and four brain regions (R1–R4) (Fig. 6). We
then calculated the fraction of genes that were expressed
with Spearman’s correlation coefficient >0.5 compared
to BRD1 for each of the 32 intervals. Previously we
showed that the majority of genes in the BRD1 network
are positively correlated with BRD1 expression across all
samples in Brainspan, including the BRD1 PPI networks.
To gain insight into which spatiotemporal intervals that
may be driving this positive correlation, we investigated
the fraction of BRD1 co-expressed genes in the BRD1-S
and BRD1-L PPI networks and compared them to the
background fraction across all genes in the Brainspan
dataset. A higher fraction of co-expressed genes was
Fig. 5 Disease risk gene analysis of the BRD1 network. Enrichment for genetic disease risk was investigated for seven BRD1 sub-networks across
12 GWASs comprising eight brain disorders and four disorders that are not considered brain disorders. The bars indicate BRD1 sub-networks in
the order: all BRD1-S and BRD1-L PTGs and PPIs (black), BRD1-S PTGs and PPIs, BRD1-S PTGs, BRD1-S PPIs, BRD1-L PTGs and PPIs, BRD1-L PTGs, and
BRD1-L PPIs. GWAS from the left are: schizophrenia (scz) [4, 32], attention deficit hyperactivity disorder (adhd) [27, 32], major depressive disorder
(mdd) [28, 32], autism spectrum disorder (asd) [32], bipolar disorder (bip) [30, 32], psychiatric cross-disorders (cross) [25, 32], anorexia nervosa (an)
[23, 32], Alzheimer’s disease (alz) [24, 37], Crohn’s disease (crohns) [36], rheumatoid arthritis (ra) [29, 33], coronary artery disease (cad) [31, 34], and
type 2 diabetes (t2d) [26, 35]. The red line indicates P = 0.05, before correction for the number of GWAS tested. The number of significant loci as
well as the number of subjects in each study is noted under each study
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observed for both networks during pcw 16–26 (P2, sec-
ond trimester) in the prefrontal cortex regions (R2) and
the hippocampus, striatum, and amygdala regions (R3)
(Fig. 6a, top panel and Additional file 17). The BRD1-S
PPI network was found to have a higher fraction of co-
expressed genes across several spatiotemporal intervals
including P3R3, P5R1-R3, P6R1-R4, P7R4, and P8R1-3.
We then expanded the analysis to include the entire
BRD1 interaction network (BRD1-S and BRD1-L PTGs and
PPIs) and the BRD1 schizophrenia sub-network consisting
of the 468 genes that achieved a gene-wide P value <0.05.
The highest fraction of genes co-expressed with BRD1
consistent across all BRD1 networks was observed for pwc
16–26 (P2) in the hippocampus, striatum, and amygdala
regions (R3) (Fig. 6a). All BRD1 PTG+ PPI networks
showed a significantly higher fraction of genes co-expressed
with BRD1 in this interval (Fig. 6b and Additional file 17).
We noticed that the BRD1 schizophrenia sub-network,
across several spatiotemporal intervals, was more enriched
with genes that co-expressed with BRD1 compared to other
networks that included PTGs (Fig. 6a, bottom panel). These
intervals were largely co-occurring with those of the many
times smaller BRD1-S PPI network. The BRD1 schizophre-
nia sub-network comprised a significantly higher fraction of
genes that co-expressed with BRD1 in 12 of the total 32
spatiotemporal intervals (Fig. 6b).
Discussion
In this study we have obtained results providing novel
insights into the molecular interactions of BRD1 and its
relation to mental disorders.
The molecular function of BRD1
Our results provide confirming evidence that BRD1 is
part of a histone acetyltransferase complex comprising
ING4, ING5, MEAF6, and MYST2 [7, 49] along with
supporting evidence for BRD1 and histone H3 inter-
action [50].
Interestingly, we identify several novel protein interac-
tions that are important for chromatin modulation and
Fig. 6 Identifying spatiotemporal networks of BRD1 in the human brain. a The fraction of co-expressed genes (correlation coefficient >0.5) was
calculated for each spatiotemporal interval and each BRD1 sub-network and compared to the background of genes co-expressed with BRD1 in
the entire dataset. The color-coding denotes the fold change of the fraction of co-expressed genes compared to the background. b The fraction
of genes that co-expressed with BRD1 across each of the 32 spatiotemporal intervals was calculated for all genes (gray lines), genes in the BRD1
PTGs + PPI network (orange lines), and genes in BRD1 schizophrenia network of 468 genes (red lines). A one-sided binominal test was performed
for each BRD1 sub-network and spatiotemporal interval compared to the expected fraction in the background where the asterisk (*) denote P < 0.05
after adjusting for the number of tests. Temporal intervals (P) were grouped as follows: P1 included pcw 8–13 (first trimester), P2 included 16–26 pcw
(second trimester), P3 included 35–37 pcw (third trimester), P4 included 4–10 months, P5 included 1–4 years, P6 included 8–13 years, P7 included
15–19 years, and P8 included 21–40 years. Brain regions (R) were grouped as follows: R1 included the posterior inferior parietal cortex, primary auditory
cortex, primary visual cortex, superior temporal cortex, and inferior temporal cortex; R2 included the primary somatosensory cortex, primary motor
cortex, orbital prefrontal cortex, dorsolateral prefrontal cortex, medial prefrontal cortex, and ventrolateral prefrontal cortex; R3 included the striatum,
hippocampus, and amygdala; and R4 included the mediodorsal nucleus of the thalamus, and cerebella cortex
Fryland et al. Genome Medicine  (2016) 8:53 Page 15 of 20
gene regulation, including PBRM1 which is part of the
SWI/SNF chromatin remodeling complex PBAF [64]
and the 14-3-3 proteins YWHAE, G, H, and Z. Among
several known functions, 14-3-3 proteins facilitate the re-
cruitment of transcription factors to chromatin particu-
larly in conjunction with phosphorylated histone H3S10
and H3S28 [51, 65, 66], e.g. the PBAF complex is recruited
to chromatin via the 14-3-3 proteins and phosphorylated
histone H3S10 [64]. Our results identify both BRD1 iso-
forms to bind 14-3-3 proteins as well as PBRM1 indicating
that BRD1 plays a role in chromatin remodeling.
Although the identified PPI networks of BRD1-S and
BRD1-L seem to comprise a common set of core pro-
teins, we identify several isoform-specific PPIs that could
indicate a significant functional difference between the
two isoforms. For instance, the histone methyltransferase
SUV420H1 was identified only for the BRD1-S isoform
and QSER1, a relatively uncharacterized protein, was
only identified for BRD1-L. In addition, BRD1-S and
BRD1-L had a relatively limited overlap of PTGs as well
as DEGs suggesting that these two isoforms, although
very similar in amino acid sequence, target and regulate
different gene sets. By integrating ChIP-seq and expres-
sion data, we were able to show that BRD1-S primarily
regulate gene expression in proximity to TSSs while
BRD1-L, in addition to regulating gene expression in
proximity to TSSs, has the capacity to regulate gene
expression further up- and downstream from its binding
sites. Based on our observations, it is tempting to specu-
late that BRD1-L is involved in mediating chromatin loop
status thereby regulating the expression of distal genes
similar to the mechanisms identified for SATB1 [67]. Con-
versely, BRD1-S may primarily regulate gene expression
by binding in close proximity to the TSSs of genes and by
mediating acetylation of histones, in particular acetylation
of histone 3 lysine 14, and chromatin remodeling through
its interactions with MYST2 [7] and PBRM1, respectively.
The BRD1 interaction networks and their relation to
mental disorders
Several studies have implicated 14-3-3 genes with schizo-
phrenia and bipolar disorder [52–55, 68], YWHAE and
YWHAZ interact with disrupted in schizophrenia 1
(DISC1) [69], and Ywhae+/– and Ywhaz–/– mice have been
shown to display neurodevelopmental and schizophrenia-
associated phenotypes [70, 71]. Furthermore, the PBRM1
gene has been associated with susceptibility to schizophre-
nia and bipolar disorder [4, 30, 56–58, 72, 73]. Our finding
that these proteins all interact with BRD1 provides a novel
line of evidence implicating the network of BRD1,
PBRM1, and 14-3-3 proteins with schizophrenia and bipo-
lar disorder.
In addition to the similarities and differences of the mo-
lecular and cellular functions of BRD1-S and BRD1-L, we
explored their interaction networks for enrichment of dis-
ease risk. We observed that the entire BRD1 network is
enriched for schizophrenia risk and we found that the
BRD1-S network was generally more enriched with
schizophrenia risk and perhaps other mental disorders
compared to BRD1-L. Moreover, the entire BRD1 network
was more enriched with schizophrenia compared to the
BRD1-S network, suggesting an enhanced effect of com-
bining the networks from both isoforms. Our results sup-
port a recently published large-scale study of autism risk
genes which demonstrates the importance of considering
splice isoforms when exploring disease networks [74]. It
should be noted that the identified BRD1 networks were
not identified in brain-derived cells. However, our integra-
tive analysis using spatiotemporal expression data from
the human brain suggest that the identified interactions
may also be occurring and operating in the human brain.
Although the BRD1 interaction network was not iden-
tified to be enriched with bipolar disorder risk genes, it
is reasonable to speculate that this difference is based on
power constraints in the original GWAS rather than on
a less prominent role of BRD1 in the etiology of bipolar
disorder. Future studies in larger bipolar disorder GWAS
datasets are warranted to confirm this hypothesis. In
general, the smaller GWAS sets may be underpowered
which should be taken into consideration when inter-
preting the results.
Further integrative analyses using spatiotemporal tran-
scriptome data from the human brain suggested that
both BRD1-S and BRD1-L interaction networks play a
role in brain function and schizophrenia, especially at
mid-fetal stages (pcw 16–26) in the hippocampus, amyg-
dala, and striatum. However, the BRD1-S networks seem
also to play a role in brain function and schizophrenia
later in life, particularly during childhood and early
adulthood. These observations are supportive of the en-
richment analysis showing the highest enrichment of
schizophrenia risk when analyzing the entire BRD1 net-
work as well as more enrichment of schizophrenia risk
when analyzing the BRD1-S network compared to the
BRD1-L network.
Conclusions
Here we expand the molecular and functional cha-
racterization of BRD1 and provide evidence that BRD1
acts as a regulatory hub in a comprehensive schizophrenia
risk network and possibly risk networks for other mental
disorders as well, thereby supporting previous association
studies implicating the BRD1 gene with schizophrenia and
bipolar disorder [1–6]. Furthermore, we identify spatio-
temporal intervals in the human brain where BRD1 sub-
networks are likely to play a role in brain function and
schizophrenia. These results encourage further research of
BRD1, for example using in vivo models.
Fryland et al. Genome Medicine  (2016) 8:53 Page 16 of 20
Additional files
Additional file 1: Immunofluorescence staining of HEK293T cells stably
expressing V5-epitope tagged BRD1-S and BRD1-L. Stable cell lines
(BRD1-S-V5 and BRD1-L-V5) and the untransfected HEK293T cell line
(HEK293T) were cultured for 48 h in 2 mL slide flasks followed by fixation
in 2 % freshly prepared paraformaldehyde solution. Slides were incubated
with anti-V5 antibody (Invitrogen), washed, and incubated with anti-mouse
immunoglobulins/FITC F(ab’)2. Cell nuclei were stained by Hoechst staining.
From the left: immunoflourescence staining of cell nuclei (Hoechst, blue),
imunnoflourescence staining of V5-tagged BRD1-S and BRD1-L (Anti-V5,
green), and the two images merged (Merge, purple). (PDF 94 kb)
Additional file 2: Expression arrays from siRNA knockdown and
over-expression. After RNA purification from BRD1-S, BRD1-L and HEK293T
cells, and cells treated with siRNA directed against BRD1 and cells treated
with scrambled siRNA, expression microarray analyses were performed
on Affymentrix U219 chips. Individual probe emission intensities were
normalized to the mean intensity of the entire array and differential
values were calculated as log2(sample) – log2(control) and a cutoff value
of +/– 1.5-fold determined if genes were considered upregulated or
downregulated. The figure shows MA-plots, where M = log2(sample) –
log2(control) and A =½ × (log2(sample) – log2(control). The two horizontal
lines represent 1.5 in expression fold change compared to controls. Probes
regulated more than 1.5-fold are indicated by red dots. Probes that are not
regulated more than 1.5-fold are colored blue. MA-plots from the top:
(A) BRD1-S-V5 stable cells vs. control, BRD1-L-V5 stable cells vs. control and
(B) cells treated with siRNA directed against BRD1 vs. cells treated with
scrambled siRNA (2 array for method 1, M1.1, and M1.2, and 1 for method 2,
M2), and control vs. control (ctrl_v_ctrl, from HEK293T cells treated with
scrambled siRNA). The MA-plot of two independent siRNA knockdown
control experiments (ctrl_v_ctrl) showed 0.5 % of the probes below or above
a 1.5-fold threshold from a total of 49,386 probes. On average, the analysis
showed 4.4 % of the probes to be within threshold limits. (PDF 225 kb)
Additional file 3: Immunoprecipitation of PBRM1 and identification of
BRD1-S and BRD1-L by western blotting. Co-immunoprecipitations of
endogenous PBRM1 were performed on BRD1-S, BRD1-L, and untransfected
HEK293T cells, by either including antibody against PBRM1 (AB +) or by not
including antibody (AB –). BRD1-S-V5 and BRD1-L-V5 were visualized on
the western blot using anti-V5 antibody (Invitrogen) and HRP-conjugated
anti-mouse IgG antibody. Crude cell extracts (E) from BRD1-S-V5
and BRD1-L-V5 were included as migration markers of the epitope tagged
proteins, at approximately 130 kDa and 140 kDa, respectively. (PDF 122 kb)
Additional file 4: Supporting information for ChIP-seq analysis.
A Fragmented DNA for ChIP-seq, with an average size of 100–150 bp from
HEK293T cells and stable BRD1-S-V5 and BRD1-L-V5 expressing HEK293T cells.
B IP-western blot of IPed BRD1-S-V5 and BRD1-L-V5 using V5-ChIP-protocol.
V5-tagged BRD1-S and BRD1-L was IPed from stable expressing HEK293T
cells using anti-V5 antibody conjugated agarose beads (IP-V5) or anti-HA
antibody conjugated beads (IP-HA) as control IP. V5-tagged BRD1-S and
BRD1-L were visualized on a western blot using an anti-V5 antibody
(Invitrogen) and a HRP-conjugated anti-mouse IgG. (PDF 78 kb)
Additional file 5: ChIP-seq mapped reads. This file contains the number
of mapped reads for all ChIPseq analyses. (PDF 21 kb)
Additional file 6: Chromatin binding profiles for BRD1-S and BRD1-L in
relation to identified epigenetic marks in HEK293 cell lines. ChIP-seq data
(fastq files), from HEK293 cell lines and cell line derivatives, were obtained
from the ENCODE project and mapped to hg19 (for further details see
Methods). An in-house histone H3K9ac ChIP-seq dataset was also included
in the analysis. The minimum distance from (A) BRD1-S or (B) BRD1-L
ChIP-seq peak to transcription factor binding site or histone mark
was identified for all 2205 and 1722 peaks, respectively. The results
were summarized as histograms with a +/– 30 kb window from BRD1
binding (distance from BRD1 peaks). The number of peaks within
each of the summed bins (columns) can be read on the y-axis (number of
peaks). Random ChIP-seq peak regions (Random), with the same composition
of chromosomes and peak region sizes, were generated to evaluate if the
results could be explained be chance. (PDF 635 kb)
Additional file 7: Primers used in ChIP-QPCR and mRNA expression
analyses. This file contains primer sequences used for ChIP-QPCR verification
of ChIPseq peaks located in the promoter regions of five selected genes.
(PDF 21 kb)
Additional file 8: Verification of five selected ChIP-seq promoter targets
by ChIP-QPCR. From the 251 common promotor target genes (PTGs) of
BRD1-S and BRD1-L, we selected five for validation with ChIP-QPCR.
A The promoter loci at the WD repeat domain 7 (WDR7), digestive organ
expansion factor homolog (C1ORF107 or DIEXF), proteasome subunit β
type, 2 (PSMB2), ZC3H15, and zinc finger protein 226 (ZNF226) showed
BRD1-S and BRD1-L binding, while the promoter loci of the lymphocyte
expressed gene granzyme M (GZMM) showed no significant binding of
the BRD1 isoforms and was subsequently selected as a negative control.
The BRD1-S or BRD1-L binding is shown in black whereas the control
ChIP-seq (IP with anti-HA antibody) is shown in pink. B Primers were
designed to amplify a 80–150 bp sequence in the promoter region or the
intron of all six genes (for primer sequences see Additional file 7).
ChIP was performed with either anti-V5 antibody (V5) conjugated beads or
anti-HA (HA) conjugated beads using extracts from BRD1-S, BRD1-L, or
HEK293T cells (for further details see “Methods”). ChIP-QPCR showed higher
enrichment of BRD1-S and BRD1-L at the promoter loci of WDR7, DIEXF,
PSMB2, ZC3H15, and ZNF226 compared to controls. Also ChIP-QPCR showed
less BRD1-S and BRD1-L binding at introns of WDR7, DIEXF, PSMB2, ZC3H15,
and ZNF226 while ChIP-QPCR showed lower and approximately equal BRD1-S
and BRD1-L binding at the GZMM promoter and intron. (PDF 433 kb)
Additional file 9: Ingenuity pathway analysis of BRD1 interaction
networks. This Excel file includes three spreadsheets containing enriched
categories, sub-categories, and canonical pathways identified by
Ingenuity pathway analysis on the BRD1 interaction network. (XLSX 34 kb)
Additional file 10: Upregulation of BRD1-S and BRD1-L. A QPCR
measurement of BRD1 mRNA in BRD1-S and BRD1-L cells showed a ~24-fold
higher BRD1 mRNA levels compared to HEK293T controls (*P <0.0001). Error
bars indicate the standard error of the mean from n = 2 independent RNA
samples. B Western blotting analysis using an antibody against endogenous
BRD1 (BRD1 S/L) showed high levels of BRD1-S and BRD1-L in the stable cell
lines compared to the expression level of BRD1 in HEK293T cells (293 T).
D Expression array data showing log2 fold change values for probes that
target BRD1 and seven housekeeping genes: Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), Ubiquitin C (UBC), TATA box binding protein
(TBP), hypoxanthine phosphoribosyltransferase 1 (HPRT1), Beta Actin (ACTB),
Beta-2 microglobulin (B2M), and glucuronidase beta (GUSB). (PDF 76 kb)
Additional file 11: Knockdown of endogenous BRD1 using pools of small
interfering RNAs (siRNAs). In order to downregulate the endogenous BRD1
level, (A) HEK293T cells were treated with two different pools of four
different siRNA directed against BRD1 (BRD1 siRNA) and scrambled siRNA
(Ctrl siRNA) as a control. Kits from Dharmacon (Method 1) and Qiagen
(Method 2) were used at concentrations of 12.5 and 5.5 nM, respectively,
and cells were harvested 24 h after transfection followed by QPCR
measurement of BRD1 mRNA. BRD1 mRNA levels were significantly lower
(approximately 70–80 % reduction for method 1 and 60 % for method 2) in
cells treated with BRD1 directed siRNA compared to cells treated with
scrambled siRNA (***P <0.0001). The knockdown experiments showing
80 %, 70 %, and 60 % decreased levels of BRD1 mRNA are referred to as
KD1, KD2, and KD3, respectively. Error bars indicate the standard error of the
mean (SEM) from n = 3 independent RNA samples. B Expression array data
showing log2 fold change values for probes that target BRD1 and seven
housekeeping genes: Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), Ubiquitin C (UBC), TATA box binding protein (TBP),
hypoxanthine phosphoribosyltransferase 1 (HPRT1), Beta Actin (ACTB), Beta-2
microglobulin (B2M), and glucuronidase beta (GUSB). C Western blot of siRNA
silencing of endogenous BRD1 in HEK293T cells using method 1 and 2. BRD1
directed siRNA silencing and control transfections with scrambled siRNA
(Ctrl siRNA/Unspecific siRNA) was performed at increasing concentrations.
The starting concentrations are approximately 50 % of the manufacturer’s
recommended concentrations. D Photometric analysis of western blot in (B),
showing decreased levels of BRD1 in cells treated with BRD1 directed siRNA.
The BRD1 band intensities are normalized to beta-tubulin intensities and are
shown as relative to the highest value. (PDF 165 kb)
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Additional file 12: Metadata and statistics of integrative ChIP-seq and
expression analysis. This file contains three Excel spreadsheets. Spreadsheet
1 contains information on the number of genes common to both the exon
expression array and ChIPseq analyses. Spreadsheets 2 and 3 include
statistical and permutation tests concerning enrichment of DEGs among
BRD1 PTGs. (XLSX 12 kb)
Additional file 13: Integrative analysis of ChIP-seq and gene-expression
data. In order to investigate the gene-regulatory potential of BRD1-S and
BRD1-L, ChIPseq data were integrated with expression data. A window
of +/– 200 kb from BRD1 binding was constructed, fragmented in 9 kb
segments, and determined the number of DEGs having TSSs in these
segments. As opposed to the 10 kb segment used in the main manuscript
the 9 kb segments used here span across 0 on the x-axis. A, B The analysis
was performed for DEGs identified after upregulating BRD1-S or BRD1-L
or (C, D) downregulating endogenous BRD1. Significantly more up- or
downregulated genes were identified in segments where BRD1-S or BRD1-L
binds in close proximity to TSSs compared to all segments across the
window (P <0.001, 1-sample Student’s t-test). E, F The analysis was also
performed after upregulating BRD1-S or BRD1-L and using a narrow
window of +/– 5 kb from BRD1 binding sites. In order to investigate the
BRD1 gene-regulatory potential while considering all genes on the array
(and not only DEGs), probes were segmented according to TSS distance
from BRD1 binding site following calculation of the average fold change of
all probes within windows +/– 10 kb and +/– 200 kb from BRD1binding
sites. F, G These two analyses show the mean expression fold changes
combined from several genes and their distance from either BRD1-S or
BRD1-L binding on the genome. F The first analysis shows the mean probe
fold change in segments of 400 probes and using a +/– 10 kb window.
G The second analysis shows the mean probe fold change in segments of
500 probes and using a +/– 200 kb window. (PDF 753 kb)
Additional file 14: Ingenuity pathway analysis of DEGs after overexpressing
either BRD1-S or BRD1-L. This Excel spreadsheet contains a list of enriched
canonical pathways identified by Ingenuity pathway analysis using the
identified DEGs after upregulating either BRD1-S or BRD1-L. (XLSX 16 kb)
Additional file 15: Spatiotemporal mRNA expression of BRD1 in human
brain. A RNA-seq data (obtained from Brainspan; http://www.brainspan.org)
showing the temporal expression of BRD1 across 26 brain regions; primary
auditory cortex, core (A1C), amygdaloid complex (AMY), cerebellar cortex
(CBC), cerebellum (CB), caudal ganglionic eminence (CGE), dorsolateral
prefrontal cortex (DFC), dorsal thalamus (DTH), hippocampus (hippocampal
formation) (HIP), posteroventral (inferior) parietal cortex (IPC), inferolateral
temporal cortex (area TEv) (ITC), lateral ganglionic eminence (LGE), primary
motor cortex (area M1) (M1C), primary motor-sensory cortex (samples)
(M1C-S1C), mediodorsal nucleus of thalamus (MD), anterior (rostral) cingulate
(medial prefrontal) cortex (MFC), medial ganglionic eminence (MGE),
occipital neocortex (Ocx), orbital frontal cortex (OFC), parietal neocortex
(PCx), primary somatosensory cortex (area S1) (S1C), posterior (caudal)
superior temporal cortex (area 22c) (STC), striatum (STR), temporal neocortex
(TCx), upper (rostral) rhombic lip (URL), primary visual cortex (striate cortex)
(V1C), ventrolateral prefrontal cortex (VFC). Age on the x-axis is shown as
log10(days) (log10(age)) and the gene expression is shown as the average
reads per kilobase per million (avg_rpkm). B Expression microarray data
(obtained from the Human Brain Transcriptome, HBT; http://hbatlas.org)
showing the temporal expression of BRD1 across six brain regions:
neocortex (NCX), hippocampus (HIP), amygdala (AMY), striatum (STR),
mediodorsal nucleus of thalamus (MD), cerebellar cortex (CBC). Both datasets
show high expression of BRD1 in early fetal stages (until approximately day
180) and both datasets show high expression of BRD1 in the cerebellar
cortex throughout the timeline of the datasets. (PDF 208 kb)
Additional file 16: Supporting information for the gene-set enrichment
analyses using MAGMA. This file contains two Excel spreadsheets.
Spreadsheet 1 contains gene-wide and experiment-wide significant
genes from the gene-set enrichment analysis of the BRD1 interaction
network and schizophrenia. Spreadsheet 2 contains all BRD1 gene sets
used in the analysis. (XLSX 45 kb)
Additional file 17: Spatiotemporal co-expression landscapes of BRD1-S
and BRD1-L PPIs and PTGs in the human brain. The fraction of
co-expressed genes with BRD1 across 32 spatiotemporal intervals. A The
fraction of genes co-expressed with BRD1 across all genes (gray) and genes
in the BRD1-S and BRD1-L PPI networks (red and orange). None of these
were significant at P <0.05 after adjusting for multiple tests. (#) denotes
P <0.05 before correcting for multiple testing. B The fraction of genes
co-expressed with BRD1 across all genes (gray) and genes in the BRD1-S
and BRD1-L PTGs + PPI networks (red and orange). A one-sided binominal
test was performed for each BRD1 sub-network and spatiotemporal interval
compared to the expected fraction in the background where the asterisk (*)
denotes P <0.05 after adjusting for multiple tests. (PDF 322 kb)
Abbreviations
BRD1: Bromodomain containing 1; DEG: Differentially expressed gene;
IPA: Ingenuity pathway analysis; PBAF: Polybromo-associated BRG1 associated
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